Core Insights - The 44th J.P. Morgan Healthcare Conference showcased multidimensional development opportunities in the innovative pharmaceutical industry [1] - Chinese pharmaceutical companies are seeking international collaboration by showcasing clinical results and technological advantages, accelerating integration into the global biopharmaceutical industry [1] - Several Chinese pharmaceutical companies engaged in external licensing collaborations during the conference, highlighting China's leading position in the global biopharmaceutical sector [1] Investment Focus - The Hang Seng Biotechnology Index focuses on innovative pharmaceuticals, characterized by three main advantages: gathering industry leaders, scarce futures liquidity, and high elasticity & high Sharpe ratio [1] - Investors looking for convenient access to core leaders in the innovative pharmaceutical sector can consider the Hang Seng Biotechnology ETF (520933) for streamlined investment [1]
JPM 2026创新药行业呈现多维度的发展机遇，关注恒生生物科技ETF国泰（520933）投资价值
Mei Ri Jing Ji Xin Wen·2026-01-16 08:07